This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris
Ticker(s): AZN, APLSWho's the expert?
Institution: Northwestern University Feinberg School of Medicine Northwestern University
- Attending Physician, Hematology, Oncology, Neuro-Oncology & Stem Cell Transplantation
- Expertise in cancer and blood disorder, non-malignant hematology; Hemoglobinopathy; Sickle cell disease; Thalassemia; Other hemoglobin disorders; Malignant hematology
- Completed a number of oncology publications and presentations
- Manages 12 patients with PNH
- Has prescribed Epaveli to 2 patients
Interview GoalTo discuss the standard of care in treating PNH and discuss the relevance of Danicopan in this space
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
